BioLineRx (BLRX) Accumulated Expenses (2016 - 2022)

BioLineRx's Accumulated Expenses history runs 7 years deep, the most recent figure standing at $1.1 million for Q4 2022.

• In Q4 2022, Accumulated Expenses rose 271.1% year-over-year to $1.1 million; the TTM figure through Dec 2022 stood at $1.1 million (up 271.1% YoY), while the FY2022 annual figure was $1.1 million, up 271.1% from the prior year.
• Accumulated Expenses was $1.1 million for Q4 2022 at BioLineRx, up from $301000.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $1.1 million in Q4 2022 to a low of $287000.0 in Q4 2018.
• Historically, Accumulated Expenses has averaged $581200.0 across 5 years, with a median of $474000.0 in 2020.
• The sharpest annual moves came in 2021 and 2022: Accumulated Expenses slumped 36.5% in 2021, then jumped 271.1% in 2022.
• A 5-year view of Accumulated Expenses shows it stood at $287000.0 in 2018, then jumped by 153.31% to $727000.0 in 2019, then tumbled by 34.8% to $474000.0 in 2020, then plunged by 36.5% to $301000.0 in 2021, then surged by 271.1% to $1.1 million in 2022.
• The last three Accumulated Expenses figures came in at $1.1 million (Q4 2022), $301000.0 (Q4 2021), and $474000.0 (Q4 2020), per Business Quant data.